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Abstract The use of cell surface antigens to characterise embryonic stem (ES) cells, and to monitor their differentiation, has had a
long history, stretching back to the early studies of differentiation antigens in the haematopoietic system, and their application to
teratocarcinomas and embryonal carcinoma (EC) cells in the laboratory mouse. A wide series of such antigens, which include both
glycolipids and glycoproteins are now extensively used in studies of human ES cells. Many of these were first identified using both
mouse and human EC cells, although the cell surface antigen phenotype of human EC and ES cells has proved to be significantly
different from that of murine EC and ES cells.
© 2009 Elsevier B.V. All rights reserved.Contents
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by red blood cells, paved the way for safe and effective
blood transfusions (Landsteiner, 1901; see Race and Sanger,
1975). Over 60 years later, incompatibility for a series of
much more polymorphic antigens expressed on human
leukocytes (the human leukocyte antigens, or HLA), but
not erythrocytes, was found to be the principal basis of the
immune rejection of transplanted organs, leading to the.
4 A.J. Wright, P.W. Andrewsdevelopment of tissue typing that underpins successful
organ transplants (Bach and Amos, 1967; Patel et al., 1968).
The MHC antigens, HLA in humans and H-2 in the mouse,
were found to be widely expressed on many cell types.
However, building on the early serology of the H-2 system,
Ted Boyse and Lloyd Old, working in the Sloan Kettering
Institute in New York in the 1960s, discovered other
antigens that were expressed only on certain cell types,
and could be used to follow differentiation and acquisition
of specific functions, particularly among the lymphocytes of
the immune system (Boyse and Old, 1969). These antigens
they called “Differentiation Antigens.” One of the early
problems with serology, before the advent of monoclonal
antibodies, was that serum from any one mouse would
contain a mixture of antibodies of different specificities,
and the nature of these would differ from one individual
mouse to another. An important insight of Boyse and Old was
to make use of polymorphic differences in particular
antigens so that antisera specificity could be controlled by
genetics. In this way, they were able to define a series of
differentiation antigens of mouse lymphocytes, for which
allelic antigenic differences could be identified. These
antigens included Thy1, a marker of thymocytes and T-
lymphocytes, and Ly1, Ly2, Ly3, and Ly5, all markers of
different subsets of T-lymphocytes, allowing the first
identification of T helper and T killer cells (Boyse and
Bennett, 1974; Cantor and Boyse, 1977).
This work provided the basis for using surface marker
antigens to characterize early embryonic cells and to study
their differentiation during embryogenesis. Before the
isolation of embryonic stem (ES) cell lines from the laboratory
mouse (Evans and Kaufman, 1981; Martin, 1981), embryonal
carcinoma (EC) cells, the stem cells of teratocarcinomas,
offered the best tool for investigating the behavior of early
embryonic, pluripotent cells. Indeed it was studies of these
tumor stem cells that paved the way for the eventual
isolation of ES cell lines; EC cells are, in effect, the malignant
counterparts of ES cells (Solter, 2006). In a seminal paper,
Artzt et al. (1973) reported immunizing 129 strain adult mice
with F9 embryonal carcinoma cells. Since the F9 cells were
also derived from a teratocarcinoma of 129 mice, which
should be tolerant to any antigens expressed in the adult,
these authors argued that the mice would only produce
antibodies to embryonic antigens expressed by the F9 cells.
Indeed these sera did recognize an antigen, the “F9 antigen”,
expressed on early preimplantation embryos, particularly the
cells of the inner cell mass (ICM), providing some of the first
evidence that EC cells resemble the pluripotent cells of the
ICM. Other polyclonal sera were also developed to character-
ize mouse EC cells and to monitor their differentiation (e.g.,
Stern et al., 1975, 1978; Jacob, 1977).
Ultimately, although some progress was made toward
identifying the nature of the antigen recognized by the F9
antisera (Muramatsu et al., 1979; Gachelin et al., 1982),
the complexity of polyclonal sera proved a significant
stumbling block in these studies, and the assumption of
tolerance to antigens expressed in the adult was never
as robust in providing controls as the use of immunoge-
netics to define allelic differentiation antigens of lym-
phocytes. Nevertheless, these early studies pointed to
the potential value of cell surface antigens for monito-
ring the differentiation of embryonic cells, and paved theway for the development of more robust cell surface
markers once monoclonal antibody technology was deve-
loped in the mid 1970s. A turning point was then the
discovery of techniques for producing monoclonal anti-
bodies (Kohler and Milstein, 1975), which provided the
approach that has since yielded the panel of marker
antigens that are now widely used to characterize human
ES cells (Andrews et al., 1996; International Stem Cell
Initiative, 2007).
Glycolipid antigens of mouse and human
embryonic stem cells
Stage-specific embryonic antigen-1
In 1978, Solter and Knowles (1978) produced a new
monoclonal antibody from lymphocytes of a mouse immu-
nized with F9 EC cells. Like the F9 serum of Artzt, this
monoclonal antibody, MC480, recognized an antigen
expressed by mouse EC cells and by the ICM of early embryos,
and was down regulated on differentiation (Solter et al.,
1979). The antigen was designated, stage specific embryonic
antigen-1 (SSEA1). It was subsequently also found to be
expressed by mouse ES cells (Martin and Lock, 1983).
Detailed biochemical studies revealed that the epitope
recognized by the antibody was the Lewis-X hapten, a
carbohydrate structure known to be related to the Lewis
blood group antigens (Gooi et al., 1981; Kannagi et al.,
1982). This carbohydrate is associated with both glyco-
sphingolipids and with high molecular weight glycoproteins
(Andrews et al., 1982b; Childs et al., 1983). It seems most
likely that the predominant specificity in the polyclonal anti-
F9 serum also recognized this same carbohydrate structure.
In humans, the Lewis-X structure (CD15) is expressed by
some myeloid cells and a variety of tumors unrelated to
teratocarcinomas, sometimes as a sialylated derivative
(Kannagi, 1997). Subsequently it was found that sialyl
Lewis-X is the ligand for E-selectin, one of a family of
adhesion molecules involved in lymphocyte and macrophage
homing to sites of inflammation and injury (Smith, 2008). A
function for the SSEA1/LeX antigen in the early mouse
embryo was also suggested by the finding that soluble
molecules carrying this carbohydrate structure could cause
decompaction of the morula stage of embryogenesis, at the
end of cleavage and before the formation of the blastocyst
(Fenderson et al., 1984; Bird and Kimber, 1984). In fact,
chemical studies suggested that the Lewis-X structure, but
not of the other related Lewis structures, would self-
aggregate, providing a possible mechanism for a role in
initiating compaction of the late cleavage stage embryos
(Eggens et al., 1989). However, despite evidence of a function
for the Lewis-X structure in lymphocyte homing, and possibly
in compaction of cleavage stage mouse embryos, there is no
good evidence for a function in EC and ES cells. Indeed, SSEA1
(–) mouse EC cell lines have been derived (Buckalew et al.,
1985; Rosenstraus, 1983; Gregorova et al., 1984).
The fact that the SSEA1/Lewis-X structure can be
expressed by various human, as well as mouse, cells initially
suggested that its expression might also be used to identify
EC cells in human teratocarcinomas. Previously, two studies
of cell lines derived from human teratocarcinomas did find
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and this was interpreted to suggest that human EC cells do
resemble their murine counterparts (Holden et al., 1977;
Hogan et al., 1977). However, more detailed studies of
an extensive panel of human teratocarcinoma cell lines
(Bronson et al., 1980; Andrews et al., 1980) showed that
although cells in these cultures often did express SSEA1, its
expression appeared to be by differentiated derivatives, and
not by the EC cells themselves.Stage-specific embryonic antigens-3 and-4
(SSEA3 and SSEA4)
Following the characterization of MC480, a second mono-
clonal antibody was produced by immunizing rats with four-
cell cleavage stage mouse embryos (Shevinsky et al., 1982).Figure 1 The structures of the glycosphinogolipid antigens that ch
series of glycolipd antigens are synthesized from a common precurso
of a third sugar (Gal, GlcNAc, or NeuNAc) determines whether a glob
synthesized. The glycolipid name and associated antigens and/or an
comprising the epitopes for SSEA1, SSEA3, SSEA4, Luke, P, and Forssm
antibody MC480 (Solter and Knowles, 1978), SSEA3 by MC631 (Shevin
Monoclonal antibodies VINIS56 and VIN2PB22 (Andrews et al., 1990),
recognize gangliosides GD3, GD2, GT3, and 9-O-acetyl-GD3, which ar
(Andrews et al., 1990, Draper et al., 2002, Fenderson et al., 1987).The monoclonal antibody produced, MC631, identified an
antigen that is expressed on cleavage stage mouse embryos,
but disappears around the time of blastocyst formation and is
absent from the ICM, although it reappears on primitive
endoderm cells. The antigen, named SSEA3, is also absent
from mouse EC and ES cells. Surprisingly, however, it
appeared that human EC cells express SSEA3 (Shevinsky
et al., 1982; Damjanov et al., 1982; Andrews et al., 1982a).
Thus human EC cells differed from mouse EC cells, not only
by lacking SSEA1 but also by expressing SSEA3. This
distinction remained when human ES cells were first derived
and proved to have a similar surface antigen phenotype to
human EC cells, contrasting with mouse EC and ES cells
(Thomson et al., 1998; Reubinoff et al., 2000; Draper et al.,
2002). Initially, this difference raised the question of
whether this reflected a difference between mouse and
human embryos, or whether human and mouse EC/ES cellsaracterize human and mouse EC and ES cells. All members of this
r, lactosyl ceramide (Galβ1→ 4Glcβ1→ ceramide). The addition
o-, lacto-, or ganglioseries oligosaccharide chain is subsequently
tibodies that define them are indicated on the right. The sugars
an antigens are also indicated. SSEA1 is defined by monoclonal
sky et al., 1982), and SSEA4 by MC813-70 (Kannagi et al., 1983).
A2B5 (Eisenbarth et al., 1979), and ME311 (Thurin et al., 1985)
e commonly induced during human EC and ES cell differentiation
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(Andrews et al., 1980, 1982a). However, studies with
human embryos revealed that they differ from mouse
embryos and their ICM cells are SSEA1(−)/SSEA3(+), corre-
sponding to the similar SSEA1(−)/SSEA3(+) phenotype of
human EC/ES cells (Henderson et al., 2002).
Biochemical studies of SSEA3 demonstrated that, like
SSEA1, the epitope is a carbohydrate and that it is
associated with a globoseries glycolipid (Fig. 1). Another
antibody, MC813-70, produced this time by immunizing with
human EC cells, was found to recognize a similar antigen,
named SSEA4 (Kannagi et al., 1983) In this case the epitope
is associated with the same globoseries glycolipid, but is
dependent on a terminal sialic acid moiety, which is not
required for SSEA3 reactivity. It seems likely that a
particular globoseries glycolipid, sialyl-gal-globoside con-
tains both the SSEA3 and the SSEA4 epitopes—SSEA3 is an
internal structure and can be recognized whether or not it is
sialyated, whereas the SSEA4 epitope overlaps and includes
the terminal sialic acid (Kannagi et al., 1983; Fenderson
et al., 1987). The expression of SSEA3 and SSEA4 was
correlated in both mouse embryos and human EC/ES cells,
as would be anticipated for epitopes associated with the
same molecule.
Globoside, the tetrasaccharide glycolipid from which the
globoseries glycolipids take their name, was previously
shown to correspond to the P blood group antigen (Naiki
and Marcus, 1974). The red blood cells of most humans are P-
antigen(+), but very rare individuals lack the key enzymes
that extend the precursor di-and trisaccharides to generate
globoside, and their red cells are P-antigen(−). When
expression of SSEA3 and SSEA4 was examined on red cells,
it was indeed found that red cells of P-antigen(+) individuals
also expressed, with rare exceptions, both SSEA3 and SSEA4,
whereas P-antigen(−) red cells were also SSEA3(−) and SSEA4
(−) (Tippett et al., 1986). The exceptions were that the red
cells of about 1% of P-antigen(+) individuals, which were
SSEA4(−) through SSEA3(+). This phenotype corresponded to
a previously identified P-blood group antigen named Luke:
Luke(−) red cells were also SSEA4(−) but SSEA3(+). It seems
likely, though never formally proven, that Luke(−) indivi-
duals lack the enzyme required to terminally sialylate gal-
globoside, although such a specific enzyme has been
identified (Chen et al., 1989). These observations suggest
that occasional SSEA4(−) human ES cell lines should be found,
although to date none have been reported; the rarity of the
P-antigen(−) phenotype suggests it is highly unlikely that we
will find SSEA3(−) ES cell lines, though they should be
formally possible.
The distinct expression patterns of SSEA3 and SSEA4 on
human and mouse EC/ES cells appear to be a striking species
difference. Nevertheless, mouse EC cells do express high
levels of globoseries glycolipids (Willison and Stern, 1978;
Stern et al., 1978), but they are modified differently. Mice,
but not humans, possess an enzyme that is able to add
galactosamine (globoside α-N-acetylgalactosaminyltransfe-
rase-1, a product of the Gbgt1 gene) to globoside to yield an
antigen known as the Forssman antigen. Forssman antigen is
not found in humans but it is expressed on mouse EC cells, so
that the absence of SSEA3 and SSEA4 from these cells may not
be so fundamental a difference if it is the core structure of
the carbohydrate that is important for function, rather thanthe terminal modifications containing the SSEA3, SSEA4, and
Forssman epitopes.
However, as in the case of SSEA1 on mouse EC and ES cells,
no function for SSEA3 and SSEA4 has been identified. Since
P-antigen(−), SSEA3(−), SSEA4(−) individuals develop nor-
mally, it seems that a critical function in early embryonic
development is unlikely. Certainly we and others have found
that elimination of SSEA3 and SSEA4 expression from human
EC and ES cells by inhibiting their synthesis with a specific
inhibitor of glucosyl-ceramide sythetase, PDMP, is compatible
with their retention of a stem cell phenotype (Fenderson
et al., 1993; Brimble et al., 2006). More dramatically,
Fenderson et al. (1992) found that Medaka fish embryos
develop normally in the presence of PDMP, despite a greater
than 95% reduction in their synthesis of glycolipids. These
results offer a conundrum: the various glycolipids expressed
in the early embryo, including those carrying epitopes such as
SSEA1, SSEA3, and SSEA4, are exquisitely and finely regulated
during development, and require a substantial investment by
the organism in the genes encoding the glycotransferase
enzymes involved in their synthesis; yet they are dispensable!
Perhaps their function is related to conditions in nature, and
is not relevant in the laboratory setting. However, no matter
what the explanation, these antigens do provide valuable
markers of EC and ES because of their carefully controlled
developmental regulation. Interestingly they do have a
relevance to pathology, since it is known that women who
have red blood cells lacking expression of the P-antigen have
high rates of early spontaneous abortion (see Race and
Sanger, 1975). A possible explanation is an immune response
to SSEA3 and SSEA4 expressed on the early embryo.Glycolipid marker antigens and human EC/ES
cell differentiation
The expression of SSEA1, SSEA3, and SSEA4 are strongly
developmentally regulated in both mouse and human EC/ES
cells. In mouse EC cells, the expression of SSEA1 is rapidly
down regulated when the cells are induced to differentiate
(Solter et al., 1979), while induced expression of SSEA3 and
SSEA4 can sometime be detected, indicative of primitive
endoderm formation (Damjanov et al., 1994). Both human EC
and ES cells, unlike the corresponding mouse cells, tend to
grow poorly at low cell densities, suggestive of a requirement
of cell:cell interactions to maintain proliferation (Fox et al.,
2008). However, commonly at low densities they activate
expression of SSEA1 (Andrews et al., 1982a, 1984b). In part
this might reflect some differentiation toward the tropho-
blast lineage as these cells do express SSEA1 (Damjanov and
Andrews, 1983). For example, up regulation of SSEA1 can be
seen in some human EC and ES cells following knockdown of
OCT4 expression by RNAi (Matin et al., 2004).
NTERA2 is one human EC cell line that is capable of
differentiation under a wide variety of circumstances
(Andrews, 1984; Andrews et al., 1984b). When induced to
differentiate by exposure to retinoic acid, hexamethylene
bisacetamide, or BMP7, essentially all of the cells differ-
entiate along different pathways depending on the inducing
agent. In each case, however, the expression of SSEA3 and
SSEA4 is down regulated (Fenderson et al., 1987, Andrews
et al., 1990, 1994). Particularly in the case of retinoic acid
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associated antigens is accompanied by up regulation of both
lactoseries and ganglioseries glycolipids, each with asso-
ciated antigenic activity—SSEA1 in the case of the lactoseries
structures, but several ganglioside antigens in the case of the
gangioloseries structures (A2B5, VINIS56, VIN2PB22) (Eisen-
barth et al., 1979; Fenderson et al., 1987; Andrews et al.,
1990). Similar changes are seen during differentiation of
human ES cells (Draper et al., 2002). The synthesis of these
structures is dependent on a large array of specific glycolsyl
transferases. However, they are all synthesized from a
common precursor, lactosyl ceramide which contains a
simple disaccharide, lactose (Fig. 1). The enzyme that then
adds a third sugar to this initial core is crucial in switching
among the globo-, lacto-, and ganglio-structures, and it
seems that this is the rate-limiting step in synthesis (Chen
et al., 1989).
One curious feature of SSEA3 and SSEA4 expression is that,
although the SSEA3 epitope is an internal structure and the
SSEA4 epitope is the terminal structure of the glycolipid that
carries them (sialyl-gal-globoside), cells commonly appear to
lose SSEA3 expression before they lose SSEA4 expression
(e.g., Fenderson et al., 1987; Draper et al., 2002). This
counterintuitive observation is difficult to reconcile with a
simple view of the nature of the antigens. However, it may be
that whether the antigens are detected on the cell surface
depends on how it is displayed rather than whether or not the
glycolipids are synthesized. Following this hypothesis we
have considered that expression of SSEA3 may integrate
different information about a cell and provide a broader
indicator of “cell state” than perhaps expression patterns of
a single gene. In one study of culture adaptation of human ES
cells we analyzed SSEA3(+) and SSEA3(−) sorted subsets of an
early passage, diploid culture of the human ES cell line, H7,
and a late passage, karyotypically abnormal and “culture-
adapted” subline (Enver et al., 2005). In the early passage
line, essentially all the clonogenic cells were found in the
SSEA3(+) population, whereas clonogenic cells were found in
both the SSEA3(+) and the SSEA3(−) populations of the
culture-adapted cells. We interpreted the data by a model in
which the stem cell compartment is divided into SSEA3(+)
and SSEA3(−) substates that can interconvert. In the low
passage cells, we envisaged that the SSEA3(−) cells are
primed to continue and commit to differentiate, whereas in
the culture-adapted cells adaptation has raised the barrier
to commitment to differentiate and traps cells within the
stem cell compartment in a way that allows us to visualize
cells in the SSEA3(−) state which would otherwise be
transitory and difficult to observe.The high molecular weight proteoglycans
In addition to the glycolipid antigens, human EC and ES cells
are characterized by expression of an apparently related
series of high molecular weight glycoprotein antigens
(International Stem Cell Initiative, 2007; Andrews et al.,
1996). Two such antigens were defined by antibodies, TRA-1-
60 and TRA-1-81, produced from mice immunized with the
human EC cell line 2102Ep. These, and another antigen,
defined by a separately produced antibody, 8-7D, were down
regulated on EC cell differentiation (Andrews et al., 1984a).By immunoprecipitation of lysates from surface iodinated
cells, the antigens were found to be different high molecular
weight proteins of similar size (MW approx 200,000−
400,000). Other similar antigens, GCTM2, and K4 and K21,
were identified in other studies (Pera et al., 1988; Rettig
et al., 1985). Further study suggested that these were high
molecular weight proteoglycans containing chondroitin
sulfate and keratan sulfate glucosaminoglycan (GAG) chains
(Badcock et al., 1999; Cooper et al., 1992, 2002). Strikingly,
however, in contrast to the original reports, when these
antigens were isolated by immunoprecipitation and probed
in Western blots, it was evident that the same molecules
carried the different epitopes defined by these different
antibodies (Badcock et al., 1999). In many cases it seemed
that these epitopes were associated with the carbohydrate
rather than the protein backbone. The most likely explana-
tion for these results is that the antigen consists of a common
proteoglycan, that may be differentially modified to yield
the different epiptopes detected, and that different
molecules may contain different constellations of epitopes,
but not necessarily all. Although at least one of the
antibodies in this family, GCTM2, has been reported to
recognize the core protein, the core protein has not yet
been definitively characterized. It has been suggested that it
may be related to podocalyxn (Schopperle et al., 2003;
Schopperle and DeWolf, 2007), but this has been disputed
(Laslett et al., 2007). However, it is possible that there are
several core proteins that carry the GAGs containing the
different epitopes.
Although at least some of the epitopes of this family of
high molecular weight protein antigens appear to be human
specific, such structures do occur in mouse embryos and
mouse EC/ES cells as well (Muramatsu et al., 1978). Indeed
the SSEA1 determinant has also been reported to be
associated with a high molecular weight glycoprotein
(Andrews et al., 1982b; Childs et al., 1983). It is notable
that the core carbohydrate of the SSEA1 antigen is
polylactosaminoglycan, which is also the core of keratan
sulfate, one of the GAGs associated with the high molecular
weight proteoglycan antigens of human EC/ES cells.Other protein markers
Apart from those antigens that have been specifically
identified by immunizing mice with embryonic cells, human
EC and ES cells express a wide variety of other antigens that
can be useful as markers in particular situations. One set that
has been extensively studied is the class 1 MHC antigens.
Mouse EC and ES cells do not express H-2 class 1 antigens, but
it is well documented that both human EC and ES cells
express HLA class 1, though not class 2, antigens at low but
significant levels (Andrews et al., 1981, 1982, 1984b, 1996;
Bronson et al., 1980; Draper et al., 2002; Drukker et al.,
2002, 2006; International Stem Cell Initiative, 2007). In some
cases expression is up regulated on differentiation. However,
just as in the case of H-2 in mouse EC/ES cells, the expression
of HLA is also up regulated by interferon, especially
interferon gamma (Andrews et al., 1987; Draper et al.,
2002; Drukker et al., 2002).
Alkaline phosphatase (ALP) is another widely used marker
that can be detected histochemically in mouse and human EC
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Antibodies are available for the human enzymes, which are
located on the cell surface and exist as several isozymes that
are immunologically distinguishable. Human EC and ES
cells express predominantly the tissue nonspecific form of
ALP which can be detected by two antibodies, TRA-2-49 and
TRA-2-54 (Benham et al., 1981; Andrews et al., 1984c).
However, EC cells also express a low percentage but
nevertheless significant level of a placental-like form of
ALP. The latter may well be a germ cell-specific form of
ALP which is also detectable immunologically (Millán and
Stigbrand, 1983; Andrews et al., 1996). However we are not
aware of studies of this isoform in human ES cells, although it
might be anticipated to be expressed.
Other antigens that have found use in the study of human
EC and ES cells include Thy1, CD9, CD30, and a pan-human
antigen, TRA-1-85. The Thy-1 antigen is another that
distinguishes mouse and human EC/ES cells. It is not
expressed by the mouse cells, but is expressed by human
EC/ES cells in which it is down regulated on differentiation
(Andrews et al., 1983, 1996; Draper et al., 2002; Interna-
tional Stem Cell Initiative, 2007). CD9 is also a widely
expressed human antigen, but it is typically expressed by
human ES cells and is down regulated on their differentia-
tion. In this connection it has been used to identify early
stages of differentiation and is potentially a valuable marker
for identifying subsets of cells that are still within the stem
cell compartment (Laslett et al., 2007; International Stem
Cell Initiative, 2007).
CD30 is an antigen associated with a receptor of
TNFalpha. It is not always expressed by human ES cells, but
it is commonly expressed by human EC cells, and also by
human ES cells that have acquired cytogenetic abnormalities
and have become “culture adapted” (Herszfeld et al., 2006).
It was suggested that this reflects a role of CD30 signaling in
preventing apoptosis and so expression of CD30 may provide
a selective advantage for variant ES cells. However, it
appears that, although this might represent one pathway by
which variant cells acquire selective advantages, other
routes are also possible (Barnes et al., in press).
TRA-1-85 is an antibody that recognizes a pan human
antigen, that is also known as the blood group antigen, Ok(a)
(Williams et al., 1988). It also corresponds to CD147. Given
its widespread distribution (it is expressed by all human cells
we have tested) it is not useful in the context of ES cell
differentiation. However, the epitope is not detectable on
mouse cells and so it does prove to be a useful marker to
distinguish human cells from mouse feeders in human ES cell
cultures. Potentially it can also be useful to identify human
tissue in mouse xenografts.Conclusion
The extensive panel of surface antigen markers that are now
widely used to monitor cultures of human ES cells was largely
developed over many years from studies on human EC cells.
They have been used to define and characterize ES cells and
to monitor their differentiation. Their patterns of expression
on human EC and ES cells are, in many cases, different from
mouse EC and ES cells, in part perhaps reflecting differences
in the biology of mouse and human embryos. In some cases,they appear to be capable of identifying stages in the process
of differentiation and subsets of cells within the stem cell
compartment itself. Mostly, these antigens are not restricted
to ES cells but may be expressed on a variety of other cell
types. Their value as markers depends very much on the
specific context in which they are used, but this is common
to the use of antigens to define almost any other cellular
system; it is rare, if it occurs at all (except for perhaps
antibody idiotypes), for an antigen to be expressed uniquely
on one cell type and no others. It is therefore certainly
important to examine the pattern of expression of several of
these antigens rather than rely on information from only one.
Also, for the most part, the antigens that are used to define
human EC and ES cells have no known function. Indeed some
seem to be dispensable and their absence does not obviously
affect the behavior of the cells. Nevertheless, provided that
their expression is robustly regulated, they remain effective
operational markers.
Beyond the antibodies now widely used, there remains
considerable scope for characterizing new reagents. It would
certainly be valuable to extend the range of markers that can
be used to refine the identification of undifferentiated cell
substates, to assess, for example, whether cells predeter-
mined for particular fates can be recognized. Also, although
many molecules on the cell surface do play key regulatory
roles, the existing markers have no obvious function. New
antibodies recognizing functional components of the ES cell
membrane might not only provide tools for probing the
mechanisms that regulate self-renewal and differentiation
of these cells, but also tools for manipulating them. In this
respect, one newly reported antibody is apparently cytotoxic
for ES cells (Choo et al., 2008), offering a potentially useful
new method for eliminating contaminating stem cells in
preparations of differentiated derivatives that might be
transplanted to a patient to restore a diseased or damaged
tissue. With a long history reaching back to the origins of our
current studies of embryonic stem cells, it is certain that cell
surface antigens will continue to provide crucial tools as we
explore further the biology of these fascinating cells, and
move toward their eventual applications in healthcare and
regenerative medicine.Acknowledgments
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